Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors

European Journal of Pharmacology

Volumn 617, Issue 1-3, 2009, Pages 23-27

  Zhu, Li Ping ^a   Xing, Jing ^a   Wang, Qing Xiao ^a   Kou, Lei ^a   Li, Chen ^a   Hu, Bi ^a   Wu, Zhi Wei ^a   Wang, Jian Jun ^a   Xu, Gen Xing ^a,b  

^a NANJING UNIVERSITY   (China)

^b Jiangsu Research Center for Gene Pharmaceutical Engineering and Technology   (China)

Author keywords

Angiogenesis; Chemotherapy; Endostatin; Synergistic interaction

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ENDOSTATIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; RECOMBINANT ENDOSTATIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; LIVER TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR MODEL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSTATINS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68749109242     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.003     Document Type: Article

References (34)

1. Abraham D., Abri S., Hofmann M., Holtl W., and Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J. Urol. 170 (2003) 1388-1393
2. Berger A.C., Feldman A.L., Gnant M.F., Kruger E.A., Sim B.K., Hewitt S., Figg W.D., Alexander H.R., and Libutti S.K. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg. Res. 91 (2000) 26-31
3. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin. Thromb. Hemost. 30 (2004) 379-385
4. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
5. Capillo M., Mancuso P., Gobbi A., Monestiroli S., Pruneri G., Dell'Agnola C., Martinelli G., Schultz L., and Bertolini F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial progenitors. Clin. Cancer Res. 9 (2003) 377-382
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
7. Cher L., Rosenthal M.A., Drummond K.J., Dally M., Murphy M., Ashley D., Thursfield V., and Giles G.G. The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998-2000. J. Clin. Neurosci. 15 (2008) 398-401
8. Cui R., Ohashi R., Takahashi F., Yoshioka M., Tominaga S., Sasaki S., Gu T., Takagi Y., and Takahashi K. Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro. Cancer Sci. 98 (2007) 830-837
9. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285 (1971) 1182-1186
10. Gentilini G., Kirschbaum N.E., Augustine J.A., Aster R.H., and Visentin G. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired down regulation of p21(Cip1/WAF1). Blood 93 (1999) 25-33
11. Ghaneh P., and Neoptolemos J. Adjuvant chemotherapy - the standard after resection for pancreatic cancer. Am. J. Surg. 194 (2007) S131-S137
12. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
13. Hanai J., Gloy J., Karumanchi S.A., Kale S., Tang J., Hu G., Chan B., Ramchandran R., Jha V., Sukhatme V.P., and Sokol S. Endostatin is a potential inhibitor of Wnt signaling. J. Cell Biol. 158 (2002) 529-539
14. Herbst R.S., Hess K.R., Tran H.T., Tseng J.E., Mullani N.A., Charnsangavej C., Madden T., Davis D.W., McConkey D.J., O'Reilly M.S., Ellis L.M., Pluda J., Hong W.K., and Abbruzzese J.L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20 (2002) 3792-3803
15. Hu B., Zhu H.W., Zhu L.P., Li C., Xu Y.F., Rong Z.G., Xu J.M., Wu Z.W., Wang J.J., and Xu G.X. Bioactivity, pharmacokinetics and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin. Acta Pharmacol. Sin. 29 (2008) 1357-1369
16. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., Flynn E., Fogler W.E., Sim B.K., Allred E.N., Pirie-Shepherd S.R., and Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61 (2001) 7669-7674
17. Kulke M.H., Bergsland E.K., Ryan D.P., Enzinger P.C., Lynch T.J., Zhu A.X., Meyerhardt J.A., Heymach J.V., Fogler W.E., Sidor C., Michelini A., Kinsella K., Venook A.P., and Fuchs C.S. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin Oncol. 24 (2006) 3555-3561
18. Lind M.J. Principles of cytotoxic chemotherapy. Medicine 36 (2008) 19-23
19. Miaskowski C., and Portenoy R.K. Update on the assessment and management of cancer-related fatigue. Princ. Pract. Support Oncol. Updates 1 (1998) 1-10
20. Nyberg P., Heikkila P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H., Pihlajaniemi T., and Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrixmetalloprotease-2, -9, and-13. J. Biol. Chem. 278 (2002) 22404-22411
21. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Cao Y., Moses M., Lane W.S., Sage E.H., and Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harbor Symp. Quant. Biol. 59 (1994) 471-482
22. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
23. Plum S.M., Hanson A.D., Volker K.M., Vu H.A., Sim B.K., Fogler W.E., and Fortier A.H. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in anorthotopic murine mammary carcinoma model. Clin. Cancer Res. 9 (2003) 4619-4626
24. Ren B., Yee K.O., Lawler J., and Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim. Biophys. Acta 1765 (2006) 178-188
25. Scappaticci F.A., Smith R., Pathak A., Schloss D., Lum B., Cao Y., Johnson F., Engleman E.G., and Nolan G.P. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 3 (2001) 186-196
26. Schuch G., Oliveira-Ferrer L., Loges S., Laack E., Bokemeyer C., Hossfeld D.K., Fiedler W., and Ergun S. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia 19 (2005) 1312-1317
27. Sorensen D.R., Read T.A., Porwol T., Olsen B.R., Timpl R., Sasaki T., Iversen P.O., Benestad H.B., Sim B.K., and Bjerkvig R. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcomal. Neuro-oncology 4 (2002) 1-8
28. Sun Y., Wang J., Liu Y., Song X., Zhang Y., Li K., Zhu Y., Zhou Q., You L., and Yao C. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 23 (2005) 7138a
29. The State Pharmacopoeia Committee of the People's Republic of China, and Beijing. Pharmacopoeia of the People's Republic of China. 2005 Ed (2005), Chemical Industry Press, Beijing 16-81 Part Sh{cyrillic}, Appendix
30. Thomas J.P., Arzoomanian R.Z., Alberti D., Marnocha R., Lee F., Friedl A., Tutsch K., Dresen A., Geiger P., Pluda J., Fogler W., Schiller J.H., and Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21 (2003) 223-231
31. Tsang Y.W., Chi K.H., Hu C.J., Tseng C.L., Tseng F.W., and Wang Y.S. Chemotherapy-induced immunosuppression is restored by a fermented soybean extract: a proof of concept clinical trial. Nutr. Res. 27 (2007) 679-684
32. Wei Y.Q., Wang Q.R., Zhao X., Yang L., Tian L., Lu Y., Kang B., Lu C.J., Huang M.J., Lou Y.Y., Xiao F., He Q.M., Shu J.M., Xie X.J., Mao Y.Q., Lei S., Luo F., Zhou L.Q., Liu C.E., Zhou H., Jiang Y., Peng F., Yuan L.P., Li Q., Wu Y., and Liu J.Y. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 6 (2000) 1160-1166
33. Xu Y.F., Zhu L.P., Hu B., Rong Z.G., Zhu H.W., Xu J.M., Wu Z.W., Wang J.J., and Xu G.X. A quantitive method for assessing the antitumor potency of human recombinant endostatin. Eur. J. Pharmacol. 564 (2007) 1-6
34. Zhang H.Y., Han Q.W., Xu Y.F., Fan Y.R., Dai Q.M., Xu J.M., Zhu H.W., Rong Z.G., Wang J.J., and Xu G.X. The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin. Cancer Biol Ther. 4 (2005) 207-212